Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Targeted therapy of cancer with radiolabeled antibodies Goldenberg DMJ Nucl Med 2002[May]; 43 (5): 693-713This review focuses on the use of radiolabeled antibodies in the therapy of cancer, termed radioimmunotherapy (RAIT). Basic problems concerning the choice of antibody and radionuclide and the physiology of tumor and host are discussed. Then follows a review of pertinent clinical publications on various radioantibody constructs in the treatment of hematopoietic and solid tumors of diverse histopathologies, grades, and stages, and in different clinical settings. Factors such as dose rate delivered, tumor size, and radiosensitivity play a major role in determining therapeutic response, while target-to-nontarget ratios and, particularly, circulating radioactivity to the bone marrow determine the major dose-limiting toxicities. RAIT appears to be gaining a place in the therapy of hematopoietic neoplasms, such as non-Hodgkin's lymphoma, with several agents advancing in clinical trials toward registration, of which one has just been approved by the FDA. Although RAIT of solid tumors has shown less progress, pretargeting strategies, such as an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery of the radiotherapeutic, appear to enhance tumor-to-nontumor ratios and may increase rad doses to tumor more selectively than directly labeled antibodies.|*Radioimmunotherapy[MESH]|Brain Neoplasms/radiotherapy[MESH]|Breast Neoplasms/radiotherapy[MESH]|Colorectal Neoplasms/radiotherapy[MESH]|Female[MESH]|Hodgkin Disease/radiotherapy[MESH]|Humans[MESH]|Leukemia, Myeloid/radiotherapy[MESH]|Lymphoma, Non-Hodgkin/radiotherapy[MESH]|Lymphoma, T-Cell/radiotherapy[MESH]|Male[MESH]|Neoplasms/*radiotherapy[MESH]|Ovarian Neoplasms/radiotherapy[MESH]|Prostatic Neoplasms/radiotherapy[MESH]|Radiotherapy Dosage[MESH] |
